专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060257960A1 Method of estimating drug metabolic activity by analyzing mutations in glucuronosyl transferase gene 失效
公开(公告)号：US20060257960A1
公开(公告)日：2006-11-16
申请号：US10524278
申请日：2003-02-13
申请人： Hiroshi Sato , Yoshihide Fujiyama , Kazuo Yamamoto
发明人： Hiroshi Sato , Yoshihide Fujiyama , Kazuo Yamamoto
IPC分类号： C12Q1/48
CPC分类号： C12Q1/6876 , C12N9/1048 , C12Q2600/106 , C12Q2600/156 , G01N2500/00
摘要： An object of this invention is to provide a method for assaying, predicting or assessing drug metabolism by effectively detecting (a) mutation(s) in a gene coding for UGT. A gene coding for UGT comprises 5 exons, and since the regions of exons 2 through 5 are common to each isoform of UGT1, by assaying a mutation in the common regions, particularly a mutation in exon 5 region, and further adding the detection of (a) mutation(s) in a plurality of exon regions, mutations of UGT1 gene can effectively assayed. A nucleic acid chip using nucleic acid probes is used as a way of detecting (a) mutation(s).

2. 发明申请

US20060135588A1 Preventive and/or therapeutic drugs for inflammatory intestinal diseases 审中-公开
标题翻译：炎症性肠病的预防和/或治疗药物
公开(公告)号：US20060135588A1
公开(公告)日：2006-06-22
申请号：US10526943
申请日：2003-09-09
申请人： Yoshio Araki , Akira Andoh , Yoshihide Fujiyama
发明人： Yoshio Araki , Akira Andoh , Yoshihide Fujiyama
IPC分类号： A61K31/4152
CPC分类号： A61K31/4152 , C07D231/20
摘要： The object of the present invention is to provide a medicament useful for preventing and/or treating inflammatory bowel disease. The present invention provides a medicament for preventing and/or treating inflammatory bowel disease which comprises as an active ingredient a pyrazolone derivative represented by the following formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof: wherein R1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R1 and R2 are combined with each other to represent an alkylene group; and R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.
摘要翻译：本发明的目的是提供可用于预防和/或治疗炎症性肠病的药物。本发明提供一种预防和/或治疗炎性肠病的药物，其包含作为活性成分的由下式（I）表示的吡唑啉酮衍生物或其生理学上可接受的盐或其水合物或其溶剂合物：其中R 代表氢原子，芳基，烷基或烷氧基羰基烷基; R 2表示氢原子，芳氧基，芳基巯基，烷基或羟烷基; 或R 1和R 2彼此结合以表示亚烷基; R 3表示氢原子，烷基，环烷基，羟基烷基，苄基，萘基，苯基或被1〜3个取代基取代的苯基由烷基，烷氧基，羟基烷基，烷氧基羰基，烷基巯基，烷基氨基，二烷基氨基，卤素原子，三氟甲基，羧基，氰基，羟基，硝基，氨基和乙酰胺基。

3. 发明授权

US07582427B2 Method of estimating drug metabolic activity by analyzing mutations in glucuronosyl transferase gene 失效
标题翻译：通过分析葡萄糖醛酸转移酶基因突变来估计药物代谢活性的方法
公开(公告)号：US07582427B2
公开(公告)日：2009-09-01
申请号：US10524278
申请日：2003-02-13
申请人： Hiroshi Sato , Yoshihide Fujiyama , Kazuo Yamamoto
发明人： Hiroshi Sato , Yoshihide Fujiyama , Kazuo Yamamoto
IPC分类号： C07H21/04 , C12Q1/68
CPC分类号： C12Q1/6876 , C12N9/1048 , C12Q2600/106 , C12Q2600/156 , G01N2500/00
摘要： An object of this invention is to provide a method for assaying, predicting or assessing drug metabolism by effectively detecting (a) mutation(s) in a gene coding for UGT. A gene coding for UGT comprises 5 exons, and since the regions of exons 2 through 5 are common to each isoform of UGT1, by assaying a mutation in the common regions, particularly a mutation in exon 5 region, and further adding the detection of (a) mutation(s) in a plurality of exon regions, mutations of UGT1 gene can effectively assayed. A nucleic acid chip using nucleic acid probes is used as a way of detecting (a) mutation(s).
摘要翻译：本发明的目的是提供一种通过有效地检测（a）编码UGT的基因中的突变来测定，预测或评价药物代谢的方法。编码UGT的基因包含5个外显子，由于外显子2〜5的区域对于UGT1的各种同种型是共同的，通过测定共同区域中的突变，特别是外显子5区域的突变，并进一步添加（ a）多个外显子区域的突变，可以有效测定UGT1基因的突变。使用核酸探针的核酸芯片作为检测（a）突变的方式。

4. 发明申请

US20060024322A1 Novel prophylactics/remedies for immunopathy 审中-公开
标题翻译：免疫疾病的新型预防措施/补救措施
公开(公告)号：US20060024322A1
公开(公告)日：2006-02-02
申请号：US11122058
申请日：2005-05-05
申请人： Takumi Sasaki , Kazuhiko Kimachi , Kenji Soejima , Yumi Kimura , Chikateru Nozaki , Yoshihide Fujiyama
发明人： Takumi Sasaki , Kazuhiko Kimachi , Kenji Soejima , Yumi Kimura , Chikateru Nozaki , Yoshihide Fujiyama
IPC分类号： A61K39/02 , C07K14/31
CPC分类号： C07K14/31 , A61K38/164 , A61K39/085
摘要： A prophylactic/remedy for immunopathy for immunopathy comprising, as an active ingredient, modifications of Staphylococcal enterotoxin B (SEB) with substitution of at least one amino acid residues within the amino acid sequence of natural type SEB, or derivatives thereof, wherein the SEB modifications or derivatives thereof have inhibitory activity on T cell activation wherein they interact with specific Vβ component of T cell receptor (TCR) but are reduced in their immunological responsiveness to SEB without inducing elimination of T cells having specific Vβ component, the elimination being normally induced by natural type SEB or recombinant wild-type SEB.
摘要翻译：一种用于免疫病的免疫病的预防/治疗方法，包括用天然型SEB的氨基酸序列取代至少一个氨基酸残基的葡萄球菌肠毒素B（SEB）或其衍生物作为活性成分的修饰，其中SEB修饰或其衍生物对T细胞活化具有抑制活性，其中它们与T细胞受体（TCR）的特异性Vbeta组分相互作用，但是其对SEB的免疫应答降低，而不诱导具有特异性Vbeta成分的T细胞的消除，通常由天然型SEB或重组野生型SEB。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式